Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic.

MLA

Rivera Mejía, Luis, et al. “Safety and Immunogenicity of Shorter Interval Schedules of the Novel Oral Poliovirus Vaccine Type 2 in Infants: A Phase 3, Randomised, Controlled, Non-Inferiority Study in the Dominican Republic.” The Lancet. Infectious Diseases, vol. 24, no. 3, Mar. 2024, pp. 275–84. EBSCOhost, https://doi.org/10.1016/S1473-3099(23)00519-4.

APA

Rivera Mejía, L., Peña Méndez, L., Bandyopadhyay, A. S., Gast, C., Mazara, S., Rodriguez, K., Rosario, N., Zhang, Y., Mainou, B. A., Jimeno, J., Aguirre, G., & Rüttimann, R. (2024). Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. The Lancet. Infectious Diseases, 24(3), 275–284. https://doi.org/10.1016/S1473-3099(23)00519-4

Chicago

Rivera Mejía, Luis, Lourdes Peña Méndez, Ananda Sankar Bandyopadhyay, Chris Gast, Sonia Mazara, Katy Rodriguez, Nadia Rosario, et al. 2024. “Safety and Immunogenicity of Shorter Interval Schedules of the Novel Oral Poliovirus Vaccine Type 2 in Infants: A Phase 3, Randomised, Controlled, Non-Inferiority Study in the Dominican Republic.” The Lancet. Infectious Diseases 24 (3): 275–84. doi:10.1016/S1473-3099(23)00519-4.